Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 501-514

  Ciardiello, Fortunato ^a   De Vita, Ferdinando ^a   Orditura, Michele ^a   De Pladdo, Sabino ^b   Tortora, Giampaolo ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Autocrine and paracrine growth control; Growth factor receptors; Monoclonal antobodies; Small molecule tyrosine kinase inhibitors

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; FLUOROPYRIMIDINE; GEFITINIB; GEMCITABINE; HR 3; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; ASTHENIA; AUSTRALIA; CANCER; CANCER GROWTH; CELL PROLIFERATION; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG TARGETING; FEVER; FOLLICULITIS; HUMAN; JAPAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0347627793     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.501     Document Type: Review

References (118)

1. SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Haematol. (1995) 19:183-232.
2. SALOMON DS, GULLICK W: The erbB family of receptors and their ligands: multiple targets for therapy. Signal (2001) 2:4-11.
3. PEDERSEN MW, MELTORN M, DAMSTRUP L, POULSEN HS: The type III epidermal growth factor receptor mutation. Ann. Oncol. (2001) 12:745-760.
4. MCCLELLAND RA, BARROW D, MADDEN T-A et al.: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology (2001) 142:2776-2788.
5. AKIMOTO T, HUNTER NR, BUCHMILLER L, MASON K, ANG KK, MILAS L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. (1999) 5:2884-2890.
6. WOSIKOWSKI K, SCHUURUIS D, KOPS GJPL, SACEDA M, BATES SE: Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res. (1997) 3:2405-2414.
7. MENDELSOHN J: The epidermal growth factor receptor as a target for cancer therapy. Endocrine-Related Cancer (2001) 8:3-9.
8. SPORN MB, TODARO GJ: Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. (1980) 303:878-880. A landmark article reviewing the autocrine hypothesis of cancer growth.
9. MENDELSOHN J, BASELGA J: The EGF receptor family as targets for cancer therapy. Oncogene (2000) 19:6550-6565. A complete review on EGFR and ErbB-2 targeting in cancer.
10. MENDELSOHN J: Blockade of receptors for growth factors: an anticancer therapy. Clin. Cancer Res. (2000) 6:747-753.
11. FAN Z, BASELGA J, MASUI H, MENDELSOHN J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. (1992) 53:4637-4642. One of the first to demonstrate experimental evidence of antitumour activity of combining an anti-EGFR agent with chemotherapy.
12. BASELGA J, NORTON L, MASUI H et al.: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. (1993) 85:1327-1333.
13. GOLDSTEIN NI, PREWETT M, ZUKLYS K, ROCKWELL P, MENDELSOHN J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. (1995) 1:1311-1318.
14. PREWETT M, ROCKWELL P, ROCKWELL RF et al.: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. Tumor Immunol. (1996) 19:419-427.
15. FAN Z, LU Y, WU X, MENDELSOHN J: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. (1994) 269:27595-27602.
16. WU X, RUBIN M, FAN Z et al.: Involvement of p27kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 12:1397-1403. Describes the mechanism of interference with cell cycle progression in cancer cells by anti-EGFR antibodies.
17. PENG D, FAN Z, LU Y, DEBLASIO T, SCHER H, MENDELSOHN J: Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. (1996) 56:3666-3669.
18. CIARDIELLO F, DAMIANO V, BIANCO R et al.: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. (1996) 88:1770-1776. The first experimental evidence of antitumour activity of blocking two signalling pathways in colon cancer cells.
19. CIARDIELLO F, BIANCO R, DAMIANO V et al.: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. (1999) 5:909-916.
20. PREWETT M, ROTHMAN M, WAKSAL H, FELDMAN M, BANDER NH, HICKLIN DJ: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin. Cancer Res. (1998) 4:2957-2966.
21. PERROTTE P, MATSUMOTO T, INOUE K et al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. (1999) 5:257-265.
22. BRUNS CJ, HARBISON MT, DAVIS DW et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. (2000) 6:1936-1948. An elegant demonstration of the anti-angiogenic effects of cetuximab.
23. CIARDIELLO F, BLANCO R, DAMIANO V et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. (2000) 6:3739-3747.
24. INOUE K, SLATON JW, PERROTTE P et al.: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. (2000) 6:4874-4884.
25. SALEH MH, RAISCH KP, STACKHOUSE MA et al.: Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother. Radiopharm. (1999) 14:451-463.
26. MILAS L, MASON K, HUNTER N et al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. (2000) 6:701-708.
27. HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. (1999) 15:1935-1940. Experimental study showing the effects of ionising radiation in combination with cetuximab.
28. BIANCO C, BIANCO R, TORTORA G et al.: Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin. Cancer Res. (2000) 6:4343-4350.
29. HUANG S-M, HARARI P: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. (2000) 6:2166-2174.
30. CIARDIELLO F, CAPUTO R, BIANCO R et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053-2063. The first study showing the antitumour activity of gefitinib in combination with various cytotoxic drugs in preclinical models.
31. CHAN KC, KNOX F, WOODBURN JR, SLAMON DJ, POTTEN CS, BUNDRED NJ: Blockade of growth factor receptors in ductal carcinoma in situ of the breast inhibits epithelial proliferation. Br. J. Surg. (2001) 88:412-418.
32. WAKELING A, GUY SP, WOODBURN JR et al.; ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor receptor signaling with potential for cancer therapy. Cancer Res. (2002) 62:5749-5754.
33. SIROTNAK FM, ZAKOWSKY MF, MILLER VA, SCHER HI, KRIS MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6:4885-4892.
34. DI GENNARO E, BARBARINO M, BRUZZESE F et al.: Critical role of both p27kip1 and p21cip1/waf1 in the antiproliferative effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J. Cell. Physiol. (2003) 195:139-150.
35. OHMORI T, AO Y, NISHIO K et al.: Low dose cisplatin can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD1839; 'Iressa') in vivo. Proc. Am. Assoc. Cancer Res. (2000) 41:A3072.
36. CIARDIELLO F, CAPUTO R, BIANCO R et al.: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. (2001) 7:1459-1465.
37. CIARDIELLO F, CAPUTO R, BIANCO R et al.: ZD1839 ('Iressa'), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int. J. Cancer (2002) 98:463-469.
38. RABEN D, HELFRICH B, PHISTRY M, BUNN P: ZD1839 (Iressa), an EGFR-TKI, potentiates radiation/chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) cell lines. 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, November 7-10 (2000) Abstract LB4.
39. WILLIAMS K, TELFER BA, STRATFORD IJ, WEDGE SR: ZD1839 (Iressa), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor potentiates radiotherapy in a human colorectal cancer xenograft model. (2002) Br. J. Cancer 86:1157-1161.
40. BIANCO C, TORTORA G, BIANCO R et al.: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 ('Iressa'). Clin. Cancer Res. (2002) 8:3250-3258.
41. HUANG S, LI J, HARARI PM: Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas. Cancer Res. (2002) 62:4300-4306.
42. NORMANNO N, CAMPIGLIO M, DE LUCA A et al.: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. (2001) 13:65-72.
43. MOULDER SL, YAKES FM, MUTHUSWAMY SK, BIANCO R, SIMPSON JF, ARTEAGA CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. (2001) 61:8887-8895.
44. ANIDO J, MATAR P, ALBANELL J et al.: ZD1839, a specific epidermal growth factor receptor (EGFR) cytosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. (2003) 9:1274-1283.
45. MOASSER MM, BASSO A, AVERBUCH SD, ROSEN N: The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. (2001) 61:7184-7188.
46. LICHTNER RB, MENRAD A, SOMMER A, KLAR U, SCHNEIDER MR: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. (2001) 61:5790-5795.
47. NORMANNO N, MAIELLO MR, DE LUCA A: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action. J. Cell. Physiol. (2003) 194:13-19.
48. MOYER JD, BARBACCI EG, IWATA KK et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57:4838-4848.
49. POLLACK VA, SAVAGE DM, BAKER DA et al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. (1999) 291:739-748.
50. BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. (2000) 18:904-914. The first cetuximab Phase I studies published.
51. ALBANELL J, CODONY-SERVANT J, ROJO F et al.: Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor a expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatment. Cancer Res. (2001) 61:6500-6510.
52. SHIN DM, DONATO NJ, PEREZ-SOLER R et al.: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. (2001) 7:1204-1213.
53. RUBIN MS, SHIN DM, PASMANTIER M et al.: Monoclonal antibody (MoAb) IMC-225, an anti-epidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc. Am. Soc. Clin. Oncol (2000) 20:A1860.
54. GUNNETT K, MOTZER R, AMATO R et al.: Phase II study of anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. (1999) 19:A1309.
55. ROBERT F, EZEKIEL MP, SPENCER SA et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. (2001) 19:3234-3243. The first clinical evidence of combining cetuximab with radiation therapy.
56. ABBRUZZESE JL, ROSENBERG A, XIONG Q et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2001) 21:A518.
57. SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2001) 21:A7.
58. SALTZ L, RUBIN M, HOCHSTER H et al.: Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2001) Abstract 559.
59. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab (Erbitux) in combination with irinotecan or as single agent in patients with EGFR-expressing, irinotecan-refractory metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2003) 23:A1012.
60. SCHOEFFSKI P, LUTZ MP, FOLPRECHT G et al.: Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2002) 22:A633.
61. ROSENBERGER AH, LOEHRER PJ, NEEDLE MN et al.: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2002) 22:A536.
62. VAN LAETHEM JL, RAOUL J-L, MITRY E et al.: Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc. Am. Soc. Clin. Oncol. (2003) 23:A1058.
63. HONG WK, ARQUETTE M, NABELL L, NEEDLE MN, WAKSAL HW, HERBST RS: Efficacy and safety of the anti-epidermal growth factor receptor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncol. (2001) 21:A895.
64. BASELGA J, TRIGO JM, BOURHIS J et al.: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on the same dose and schedule platinum-based regimen. Proc. Am. Soc. Clin. Oncol. (2002) 22:A900.
65. BURTNESS B, LI Y, FLOOD W et al.: Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGFR) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc. Am. Soc. Clin. Oncol. (2002) 22:A901.
66. ROBERT F, BLUMENSCHEIN G, DICKE K et al.: Phase IB/IIA study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced stage IV non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 23:A2587.
67. KELLY K, HANNA N, ROSENBERG A et al.: A multicenter Phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 23:A2592.
68. KIM ES, MAUER AM, TRAN HT et al.: A Phase II study of cetuximab, an IgG1 epidermal growth factor receptor-blocking antibody, in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc. Am. Soc. Clin. Oncol. (2003) 23:A2581.
69. GATZEMEIER U, ROSELL R, RAMLAU R et al.: Cetuximab (C225) in combination with cisplatin/vinorelbin versus cisplatin/vinorelbin alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2003) 23:A2582.
70. KRIS MG, HERBST R, RISCHIN D et al.: Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer (2000) 29(Suppl. 1):A233.
71. NAKAGAWA K, TAMURA T, NEGORO S et al.: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa' ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. (2003) 14:922-930.
72. FERRY D, HAMMOND L, RANSON M et al. Intermittent oral ZD1839 ('Iressa'), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a Phase I Study. Proc. Am. Soc. Clin. Oncol. (2000) 20:A5E.
73. BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types. J. Clin. Oncol. (2002) 21:4292-4302.
74. GOSS G, HIRTE H, LORIMER I et al.: Final results of the dose-escalation phase of a Phase I, dose-escalation, pharmacokinetics (PK) and pharmacodynamic study of ZD1839: NCIC CTG IND. 122. Proc. Am. Soc. Clin. Oncol. (2001) 21:A2368.
75. ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. (2002) 20:110-124. The first complete pharmacodynamic study on skin biopsies in patients treated with gefitinib.
76. LORUSSO P, HERBST RS, RISCHIN D et al.: Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res. (2003) 9:2040-2048.
77. FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2003) 22:2237-2246. The complete results of the IDEAL 1 study.
78. KRIS MG, NATALE RB, HERBST RS et al.: A Phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. (2002) 21:A1166.
79. BRACONI C, SALVAGNI S, SCARTOZZI M et al.: ZD1839 for compassionate use in pretreated patients with advanced non-small cell lung cancer (ANSCLC). Proc. Am. Soc. Clin. Oncol. (2003) 22:A2749.
80. MAINWARING MG, HAINSWORTH JD, GIAN VG et al.: Gefitinib (ZD1839) in the treatment of patients with advanced refractory non-small cell lung cancer (NSCLC):250 patients treated at the Sarah Cannon Cancer Center. Proc. Am. Soc. Clin. Oncol. (2003) 22:A2774.
81. ARGIRIS A, MITTAL N, MASTERS G: Gefitinib (ZD1839) as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:A2729.
82. GELITER A, PINO MS, CERIBELLI A et al.: Results from compassionate use of ZD1839 in pre-treated non small cell lung cancer (NSCLC): our experience. Proc. Am. Soc. Clin. Oncol. (2003) 22:A929.
83. PALLIS AG, MAVROUDIS D, ANDROULAKIS N et al.: ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer (2003) 40:301-307.
84. CERESOLI GL, GREGORC V, CAPPUZZO F et al.: ZD1839 in non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Proc. Am. Soc. Clin. Oncol. (2003) 22:A2709.
85. VILLANO JL, MAUER AM, VOKES EE: A case study documenting the anticancer activity of ZD 1839 (Iressa) in the brain. Ann. Oncol. (2003) 14:656-658.
86. WU YL, YANG X-N, GU L-J: The characteristics of patients with non-small cell lung cancer with complete response treated with Z1839. Proc. Am. Soc. Clin. Oncol. (2003) 22:A2770.
87. WONG N-S, LIM ST, LIM W-T, LEONG S-S, TAN E-H: ZD1839 is more effective in patients with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users. Proc. Am. Soc. Clin. Oncol. (2003) 22:A2790.
88. SHAH NT, MILLER VA, KRIS MG et al.: Bronchioalveolar histology and smoking history predict response to gefitinib. Proc. Am. Soc. Clin. Oncol. (2003) 22:A2524.
89. ROJO F, TABERNERO J, VAN CUTSEM et al.: Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD1839). Proc. Am. Soc. Clin. Oncol. (2003) 22:A764.
90. BASELGA J, ALBANELL J, RUIZ, A et al.: Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. Proc. Am. Soc. Clin Oncol. (2003) 22:A24.
91. ROBERTSON JFR, GUTTERIDGE E, CHEUNG KL et al.: Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a Phase II study. Proc. Am. Soc. Clin. Oncol. (2003) 22:A23.
92. COHEN EE, ROSEN F, STADLER WM: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2003) 21:1980-1987.
93. MILLER VA, JOHNSON D, KRUG LM et al.: A pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J. Clin. Oncol. (2003) 21:2094-2100.
94. GIACCONE G, GONZALES-LARRIBA JL, SMIT EF et al.: Combination therapy with ZD1839 (Iressa), an orally active, selective, epidermal growth factor receptor tyrosine inhibitor (EGFR-TKI), gemcitabine and cisplatin, in patients with advanced solid tumors: promising preliminary results on tolerability, efficacy, and pharmacokinetics. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2001) Abstract 553.
95. MANEGOLD C, GATZEMEIER U, SMITH R et al.: Final data from a pilot trial of gefitinib ('Iressa', ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer: safety and pharmacokinetics. Proc. Am. Soc. Clin. Oncol. (2003) 22:A2635.
96. RIXE O, LEMARIE E, CHOMY F et al.: Phase II combination of gefitinib ('Iressa', ZD1839) and docetaxel for non-small-cell lung cancer: clinical results and biological monitoring. Proc. Am. Soc. Clin. Oncol. (2003) 22:A177.
97. GIACCONE G, JOHNSON DH, MANEGOLD C et al.: A Phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (INTACT 1). Proceedings of the 27th ESMO Congress (2002) A4.
98. JOHNSON DH, HERBST R, GIACCONE G et al.: ZD1839 ('Iressa') in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): results from a Phase III clinical trial (INTACT 2). Proceedings of the 27th ESMO Congress (2002) 468.
99. DANCEY JE, FREIDIN B: Targeting epidermal growth factor receptor - are we missing the mark? Lancet (2003) 362:62-64. A short review of the open clinical issues regarding the use of anti-EGFR drugs in cancer therapy.
100. HERBST R, GIACCONE G, SCHILLER J et al.: Subset analysis of INTACT results for gefitinib ('Iressa', ZD1839) when combined with platinum-based chemotherapy for advanced non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:A2523.
101. HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. (2001) 19:3267-3279. The first Phase I study in cancer patients treated with erlotinib.
102. SENZER NN, SOULIERES D, SIU L et al.: Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. (2001) 21:6.
103. FINKLER N, GORDONA A, CROZIER M: et al. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. (2001) 21:831.
104. PEREZ-SOLER R, CRACHOUA A, HUBERMAN M et al.: A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2001) 21:1235.
105. BULGARU AM, MANI S, GOEL S, PEREZ-SOLER R: Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev. Anti-Cancer Ther. (2003) 3:269-279.
106. CIARDIELLO F, TORTORA: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. (2001) 7:2958-2970.
107. GRUNWALD V, HIDALGO M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. (2003) 95:851-867.
108. SALTZ LB, KIES MS, ABBRUZZESE JL, AZARNIA N, NEEDLE M: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. (2003) 23:A817.
109. CLARK GM, PEREZ-SOLER R, SIU L, GORDON A, SANTABARBARA P: Rash severity is predictive of increased survival with erlotinib HCl. Proc. Am. Soc. Clin. Oncol. (2003) 23:A786.
110. MENDELSOHN J, FAN Z: Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst. (1997) 89:341-343.
111. RYAN PD, CHABNER BA: On receptor inhibitors and chemotherapy. Clin. Cancer Res. (2000) 6:4607-4609.
112. VILORIA-PETIT A, CROMBET T, JOTHY S et al.: Acquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. (2001) 61:5090-5101. The first evidence of development of cancer cells with acquired resistance to EGFR-targeting drugs.
113. CHAKRAVARTI A, LOEFFLER JS, DYSON NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. (2002) 62:200-207.
114. BIANCO R, SHIN I, RITTER C et al.: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. (2003) Oncogene 22:2812-2822. An elegant mechanistic study on the molecular mechanisms causing relative resistance to the antitumour activity of EGFR inhibitors.
115. CIARDIELLO F, BIANCO R, CAPUTO R et al.: Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. Proc. Am. Soc. Clin. Oncol. (2003) 23:A820.
116. CIARDIELLO F, CAPUTO R, BIANCO R et al.: Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J. Natl. Cancer Inst. (1998) 90:1087-1094.
117. TORTORA G, CAPUTO R, DAMIANO V et al.: Combined targeted inhibition of bcl-2, bcl-xL, EGFR and protein kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity. Clin. Cancer Res. (2003) 9:866-871.
118. TORTORA G, CAPUTO R, DAMIANO V et al.: Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 ('Iressa') and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin. Cancer Res. (2003) 9:1566-1572.